SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) and SGLT-2 inhibitors, commonly used for blood sugar control, also offer benefits such as weight loss and reduced inflammation. Although ...

SGLT2 inhibitors and GLP-1RAs yielded lower risks for COPD exacerbation than DPP-4 inhibitors among patients with type 2 diabetes.

SGLT2 inhibitors were associated with better cardioprotective effects among older adults than younger adults with type 2 diabetes.

The use of GLP-1 receptor agonists corresponded with a lower risk for depression among older adults with type 2 diabetes ...

"The findings showed that recent glucose-lowering medications proved effective across various age and sex groups.

Researchers assess whether GLP-1 receptor agonists increase the risk of suicide, self-harm, or suicidal ideation in type 2 ...

The rates of depression were similar for the GLP-1RA group and sodium-glucose cotransporter-2 inhibitor (SGLT2i) group. However, compared to participants taking dipeptidyl peptidase-4 inhibitors ...

For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a modestly lower risk for depression compared with dipeptidyl peptidase-4 ...

However, for crude incidence rates there was an increased incidence of suicidality with GLP-1 receptor agonist vs DPP-4 inhibitor use; 3.9 vs 1.8 per 1000 person-years. HealthDay News — Glucagon ...

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

1.07 to 2.02). The researchers found no consistent evidence for sex and treatment interactions with GLP-1 receptor agonists (HR, 1.17; 95% CrI, 0.87 to 1.58 for men vs women) or SGLT2 inhibitors ...